Morgan Stanley Halozyme Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,635,308 shares of HALO stock, worth $76.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,635,308

Previous 1,284,158 27.34%

Holding current value

$76.8 Million

Previous $67.2 Million 39.14%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$51.3 - $64.42 $18 Million - $22.6 Million	351,150 Added 27.34%	1,635,308 $93.6 Million
Q2 2024 Oct 17, 2024	SELL	$37.81 - $52.4 $2.7 Million - $3.74 Million	-71,284 Reduced 5.26%	1,284,158 $67.2 Million
Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $2.7 Million - $3.74 Million	-71,284 Reduced 5.26%	1,284,158 $67.2 Million
Q1 2024 Oct 17, 2024	BUY	$33.68 - $41.95 $2.4 Million - $2.99 Million	71,284 Added 5.55%	1,355,442 $55.1 Million
Q1 2024 Aug 16, 2024	BUY	$33.68 - $41.95 $2.5 Million - $3.12 Million	74,325 Added 5.8%	1,355,442 $55.1 Million
Q1 2024 May 15, 2024	BUY	$33.68 - $41.95 $2.5 Million - $3.12 Million	74,325 Added 5.8%	1,355,442 $55.1 Million
Q4 2023 Aug 16, 2024	SELL	$33.32 - $42.1 $101,326 - $128,026	-3,041 Reduced 0.24%	1,281,117 $47.4 Million
Q4 2023 Feb 13, 2024	BUY	$33.32 - $42.1 $8.22 Million - $10.4 Million	246,702 Added 23.85%	1,281,117 $47.4 Million
Q3 2023 Nov 15, 2023	SELL	$36.46 - $44.03 $2.17 Million - $2.62 Million	-59,468 Reduced 5.44%	1,034,415 $39.5 Million
Q2 2023 Aug 14, 2023	SELL	$30.28 - $38.74 $818,528 - $1.05 Million	-27,032 Reduced 2.41%	1,093,883 $39.5 Million
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $32,169 - $54,530	-979 Reduced 0.09%	1,120,915 $42.8 Million
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $10.3 Million - $15.3 Million	257,853 Added 29.84%	1,121,894 $63.8 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $180,204 - $242,175	4,677 Added 0.54%	864,041 $34.2 Million
Q2 2022 Oct 27, 2022	BUY	$37.35 - $48.3 $16.2 Million - $21 Million	434,944 Added 102.48%	859,364 $37.8 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $16.2 Million - $21 Million	434,944 Added 102.48%	859,364 $37.8 Million
Q1 2022 Oct 27, 2022	SELL	$31.97 - $41.06 $13.9 Million - $17.9 Million	-434,944 Reduced 50.61%	424,420 $16.9 Million
Q1 2022 May 13, 2022	BUY	$31.97 - $41.06 $1.62 Million - $2.09 Million	50,783 Added 13.59%	424,420 $16.9 Million
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $282,879 - $362,267	-8,890 Reduced 2.32%	373,637 $15 Million
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $14.7 Million - $17.8 Million	382,527 New	382,527 $15.6 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.54B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account